Lunch Wrap: ASX dips as Viva Energy plunges; RIP Sir Michael Hill, jeweller
Viva Energy dives but Liontown, Ramelius, Sandfire shine
Jeweller Sir Michael Hill dies
The ASX was down 0.25% at Tuesday lunchtime on the eastern seaboard.
Markets also softened across Asia, with investors now bracing for a week of crucial economic data, which includes the Fed Reserve decision on Wednesday.
Most ASX sectors were bleeding red this morning, and discretionary was the only one offering any resistance.
Most energy stocks rose, and you can thank Donald Trump for that.
He was back with another geopolitical ultimatum, this time telling Russia it's got 10 to 12 days to pull its troops out of Ukraine or face a 100% tariff wall.
Markets didn't exactly like that, but oil sure did. Brent cracked US$70 and WTI surged 2% overnight.
In the large end of town, Woodside Energy Group (ASX:WDS) climbed 1.4% after taking the reins of Bass Strait gas operations from ExxonMobil Australia.
The move, it said, gives Woodside control over a massive east coast energy source and could unlock US$60 million in synergies, not to mention the potential to drill four new gas wells.
But not all energy names were basking in the oil glow.
Viva Energy (ASX:VEA) tumbled 9% after warning that first-half earnings were set to disappoint.
The culprits, it said, were weak convenience store sales, a 27% collapse in tobacco revenue (blame new packaging laws and black-market smokes), and refining margins that ran out of puff.
Meanwhile, lithium player Liontown Resources (ASX:LTR) fell 3% despite reporting a record $23 million in positive operating cash flow for the June quarter, and $301 million in full-year revenue.
LTR confirmed it's still on track to become Australia's first fully underground lithium operation.
Still in large caps, Ramelius Resources (ASX:RMS) popped champagne, up 2% after clocking record gold production and free cash flow in the June quarter. The miner produced over 300,000 ounces at top-end guidance and raked in nearly $700 million in free cash.
Sandfire Resources (ASX:SFR) also brought the goods: copper equivalent output up 12% in the quarter, despite floods and blackouts.
CEO Brendan Harris credited the turnaround to a 'simple strategy' and aggressive deleveraging, slicing net debt by $273 million. SFR's shares climbed 1%.
ASX SMALL CAP WINNERS
Here are the best-performing ASX small cap stocks for July 29 :
Security Description Last % Volume MktCap
RAN Range International 0.003 50% 37,086 $1,878,581
BEO Beonic Ltd 0.320 49% 139,421 $15,235,117
BSA BSA Limited 0.105 44% 2,320,025 $5,496,919
NOX Noxopharm Limited 0.130 34% 1,956,239 $28,347,081
HLX Helix Resources 0.002 33% 2,000,000 $5,046,291
D3E D3 Energy Limited 0.340 26% 374,462 $21,458,252
ALR Altairminerals 0.005 25% 15,695,023 $17,186,977
BM8 Battery Age Minerals 0.071 20% 4,593,533 $8,956,308
BDG Black Dragon Gold 0.060 20% 627,674 $15,898,303
DRE Dreadnought Resources 0.012 20% 8,277,526 $50,795,000
FBR FBR Ltd 0.006 20% 3,080,345 $28,447,261
B4P Beforepay Group 1.950 19% 129,871 $79,383,074
AJX Alexium Int Group 0.007 17% 1,757 $9,518,572
RNX Renegade Exploration 0.004 17% 912,500 $3,865,090
TON Triton Min Ltd 0.007 17% 591,070 $9,410,332
AX8 Accelerate Resources 0.008 14% 45,307 $5,720,321
RLG Roolife Group Ltd 0.004 14% 496,262 $5,574,734
RGT Argent Biopharma Ltd 0.089 14% 90,000 $5,630,286
AHL Adrad Hldings 0.750 14% 22,096 $53,660,055
NUC Nuchev Limited 0.180 13% 3,332 $23,467,622
ASQ Australian Silica 0.018 13% 196,523 $4,509,766
ATT Altitude Minerals 0.018 13% 290,000 $2,983,371
ECS ECS Botanics Holding 0.009 13% 349,222 $10,368,397
IS3 I Synergy Group Ltd 0.009 13% 2,734,827 $13,650,399
Beonic (ASX:BEO) has signed a $15.2 million contract to deploy its LiDAR passenger flow tech across seven major airports in North Africa, its largest deal in the region to date.
It will kick off with a proof-of-concept at the country's main international airport, then roll out to all seven within 12 months. Beonic's share of the deal is $10.6 million, covering an initial 2.5-year term with a three-year extension option.
Helix Resources (ASX:HLX) reckons its White Hills Project in northern Arizona could host a large-scale porphyry-style copper-gold system, based on early results.
The site shows signs of two distinct mineralisation events along a belt known for big copper and gold finds.
Historic drillholes focused only on gold and missed copper, despite rock chip samples showing grades up to 5.7% copper across a +1km anomaly zone.
White Hills spans 23km² over seven tenements, and sits just 1.5 hours from Vegas.
Black Dragon Gold (ASX:BDG) has entered the public consultation phase for its Salave Gold Project's PIER application in northern Spain, a key step toward getting the project classed as a Strategic Project under new regional investment laws. The 20-day consultation, running until 25 August, covers the proposed rezoning of farmland to industrial use for Salave's surface infrastructure. It's not the final sign-off, but a crucial legal step before the Agency makes its recommendation to the Asturian Government.
Fintech lender Wisr (ASX:WZR) surged past its own guidance with a 154% jump in loan originations to $140 million in Q4. That marks five straight quarters of growth, as demand for personal and vehicle loans climbs. Net losses and late arrears both improved, and CEO Andrew Goodwin credited tech-driven automation for the company's comeback.
ASX SMALL CAP LOSERS
Here are the worst performing ASX small cap stocks for July 29 :
Code Name Price % Change Volume Market Cap
AYT Austin Metals Ltd 0.002 -33% 1,004,003 $4,752,574
DTM Dart Mining NL 0.003 -25% 9,197,764 $4,792,222
MRQ Mrg Metals Limited 0.003 -25% 625,000 $10,906,075
SFG Seafarms Group Ltd 0.002 -25% 1 $9,673,198
ANR Anatara Ls Ltd 0.007 -22% 4,393,904 $1,920,454
GGP Greatland Resources 5.440 -21% 5,377,202 $4,621,479,027
LM1 Leeuwin Metals Ltd 0.115 -21% 857,352 $14,616,926
PRX Prodigy Gold NL 0.002 -20% 1,400,849 $15,875,278
KZR Kalamazoo Resources 0.089 -19% 4,839,858 $24,133,287
SLA Solara Minerals 0.240 -17% 94,426 $16,815,599
TMX Terrain Minerals 0.003 -17% 3,666,666 $7,595,443
IFG Infocusgroup Hldltd 0.016 -16% 1,640,572 $5,546,844
GRL Godolphin Resources 0.011 -15% 100,000 $5,835,353
CHR Charger Metals 0.051 -15% 543,152 $4,645,215
AKN Auking Mining Ltd 0.006 -14% 379,149 $4,816,814
OVT Ovanti Limited 0.006 -14% 1,632,882 $29,920,265
SP3 Specturltd 0.012 -14% 205,778 $4,436,602
TEM Tempest Minerals 0.006 -14% 233,585 $7,712,565
SRL Sunrise 1.040 -13% 313,231 $140,188,562
RTR Rumble Res Limited 0.026 -13% 999,143 $28,527,005
AON Apollo Minerals Ltd 0.007 -13% 625,000 $7,427,655
CTO Citigold Corp Ltd 0.004 -13% 30,000 $12,000,000
VR8 Vanadium Resources 0.032 -13% 3,362,648 $20,314,507
Michael Hill (ASX:MHJ) has announced the passing of its founder and non-executive director, Sir Michael Hill.
Sir Michael, who built the brand from a single store in Whang�rei into a global jewellery name, was remembered as a visionary and creative force.
He began with dreams of being a concert violinist, but turned to jewellery as a teen, making waves in the industry. MHJ shares were down 1%.
Last Orders
QPM Energy (ASX:QPM) says commissioning work on the Townsville Power Station has continued, with a number of successful extended runs completed at full load for the gas turbine and generator.
The company expects to be handed dispatch control under a new agreement over the next few days, from when a new transportation and storage agreement with North Queensland Gas Pipeline will begin as QPM looks towards dispatching the power station for extended periods and taking advantage of near-term market pricing.
Firetail Resources (ASX:FTL) has further expanded the discovery potential of its newly acquired Excelsior gold project in Nevada, with interpretation of existing data supporting both an extension of the prospective Buster trend to beyond 5km and the existence one lying parallel.
Field mapping and sampling also spotted up more undocumented exploration adits, and Firetail managing director Glenn Poole said the active exploration campaign was delivering important information as the company looks towards getting a rig on the ground and testing the project's enormous potential.
New World Resources (ASX:NWC) has entered a binding US$6.5m loan facility agreement with Kinterra to continue advancing its Antler copper project towards development in Arizona.
The proceeds are marked to meet state bonding requirements, secure key land parcels, and provide general working capital and payment of costs related to Kinterra's takeover.
In Case You Missed It
Brazilian Critical Minerals (ASX:BCM) continues to advance its flagship Ema rare earths project in Brazil on multiple fronts as offtake interest grows and BCM works to complete a key bankable feasibility study.
Nimy Resources (ASX:NIM) has capped off a gallium-focused drilling campaign with more high-grade returns as the company turns its attention towards a maiden resource.
Elevate Uranium (ASX:EL8) has entered a transformative stage in its U-pgrade™ beneficiation process, with the final factory testing and shipment of a pilot plant to Namibia on track for early next month.
At Stockhead, we tell it like it is. While QPM Energy, Firetail Resources and New World Resources are Stockhead advertisers, they did not sponsor this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Courier-Mail
19 minutes ago
- Courier-Mail
ASX lifts as energy sector leads gains
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Cheery start to the morning The ASX has started the day off with a quiet but positive open, dipping slightly at first before moving into positive territory. At the time of writing, we're up 0.17% in the first hour of trade. Energy is leading gains (+0.74%) alongside healthcare, consumer discretionary, staples and financials. Oil prices jumped 3.5% overnight to US$72.51 a barrel of brent as US President Trump threatened Russia with fresh sanctions should they fail to negotiate a ceasefire with Ukraine. Gold also ticked up 0.4% to US$3324 an ounce and iron ore appreciated 0.3% to US$98.98 a tonne as markets anticipated more thawing in US-China relations ahead of the next round of trade talks. Back on the ASX, the top 7 banks index is providing some support (+0.32%), while the ASX 200 Resources (-0.07%) and All Ords Gold (-0.03%) indices hover in vaguely negative territory and the All Tech retreats -0.76%. WINNERS Code Name Last % Change Volume Market Cap MX1 Micro-X Limited 0.084 35% 668310 $41,366,540 SFG Seafarms Group Ltd 0.002 33% 583466 $7,254,899 SP3 Specturltd 0.016 33% 3536664 $3,802,801 BSA BSA Limited 0.12 33% 4432767 $6,777,023 ECT Env Clean Tech Ltd. 0.0025 25% 4252072 $8,030,871 MOH Moho Resources 0.005 25% 880329 $2,981,656 PIM Pinnacleminerals 0.048 20% 298948 $1,818,533 H2G Greenhy2 Limited 0.019 19% 110000 $11,006,589 IPB IPB Petroleum Ltd 0.007 17% 11020 $4,238,418 M4M Macro Metals Limited 0.007 17% 325588 $23,864,505 In the news... Cold cathode x-ray technology specialist Micro-X (ASX:MX1) has tapped into a nationwide network of 700 hospitals, surgical centres and outpatient facilities with a new supply agreement through a major US healthcare provider, the first of its kind for the company. MX1 will provide its Rover Plus mobile radiology system to interested facilities over an initial agreement period of three years. The company is in discussions with a second major procurement group for a similar supply agreement. Remote surveillance company Spectur (ASX:SP3) increased both total revenue (+10%) and recurring revenue (+20%) year-on-year, bringing in positive operating cash flow of $263k for the financial year. SP3 has been aggressively restructuring in recent months, reducing staff costs from $970k in the third quarter to $715k in the fourth. The company also ramped up R&D spending in a move to upgrade cloud infrastructure and software systems. Pinnacle Minerals (ASX:PIM) is climbing despite launching a $1.76m share placement at $0.04 per share, a more than 25% discount on its intraday trading price of $0.054 a share. PIM is also offering a free attaching option at $0.08 each for every two shares subscribed for. The fresh capital will go to exploration programs at the Adina East project in Quebec next door to several significant lithium projects and Pinnacle's rare earth and heavy mineral sands projects in Australia. LAGGARDS Code Name Last % Change Volume Market Cap SCP Scalare Partners 0.14 -22% 15500 $7,530,304 CZN Corazon Ltd 0.002 -20% 4000000 $2,961,431 JAV Javelin Minerals Ltd 0.002 -20% 3415417 $15,630,562 AMS Atomos 0.005 -17% 31450 $7,290,111 SHE Stonehorse Energy Lt 0.005 -17% 100000 $4,106,610 ENT Enterprise Metals 0.003 -14% 150 $4,799,610 GTR Gti Energy Ltd 0.003 -14% 2271683 $13,029,292 M2R Miramar 0.0035 -13% 242500 $3,987,293 FHS Freehill Mining Ltd. 0.004 -11% 690000 $15,362,341 MPR Mpower Group Limited 0.008 -11% 43068 $3,093,330 This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Top 10 at 11: ASX positive after muted open as Micro-X nets first major US supply deal
Perth Now
32 minutes ago
- Perth Now
Aussie shares near all-time high after inflation cools
The local share market has spiked after softer-than-expected inflation paved the way for the Reserve Bank to cut rates next month. At lunchtime on Wednesday, the benchmark S&P/ASX200 index index was up 59.8 points, or 0.69 per cent, to 8,764.4, a level just 12 points away from its all-time high set two weeks ago. The broader All Ordinaries had gained 56.1 points, or 0.63 per cent, to 9,022.8. The ASX200 was already in the green but rose another 36 points in the hour after the Australian Bureau of Statistics released its June quarter consumer price index readout. That report showed that the RBA's preferred inflation metric, trimmed mean inflation, was 2.7 per cent in the year to June 30, in line with expectations but down from 2.9 per cent in the year to March 31. Headline inflation came in at 2.1 per cent, slightly under expectations of 2.2 per cent. Betashares chief economist David Bassanese, one of just a few economists who correctly predicted that the RBA wouldn't cut rates this month, said that an August rate cut was now a "done deal". He predicted further cuts in November and February. Eight of the ASX's 11 sectors were higher at midday, with utilities flat and energy and tech slightly lower. The heavyweight financial sector was the biggest mover, rising 1.0 per cent, with gains for all the big four banks. CBA had advanced 1.7 per cent, Westpac had climbed 1.3 per cent, NAB had added 1.0 per cent and ANZ had grown 0.7 per cent. In the mining sector, West African Resources had advanced 5.7 per cent after reporting its Kiaka goldmine in Burkina Faso was ramping up to full commercial operations after pouring its first gold on June 26. Lithium miner Pilbara and nickel, copper and cobalt miner IGO were going in opposite directions after releasing their own quarterly updates, with the former rising 5.2 per cent and the latter dropping 7.1 per cent. Mineral Resources, which likewise released quarterly figures, was up 2.9 per cent. Elsewhere in the sector, BHP had dipped 0.2 per cent and Rio Tinto had dropped 0.5 per cent, while Fortescue had grown 0.8 per cent. The Australian dollar was buying 65.19 US cents, from 65.25 US cents at 5pm on Tuesday.
News.com.au
an hour ago
- News.com.au
Health Check: Opthea investors have $80m less to fight for after cash-burning quarter
Eye drug developer Opthea's cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today's sector gains after a US deal with a mystery party The financial fallout from Opthea's (ASX:OPT) two failed eye disease trials has become starkly apparent. Despite ceasing its two pivotal phase III trials, Opthea recorded US$53.5 million ($82 million) of outflows in the June quarter. This takes residual cash to US$48.4 million, from US$101.4 million as at the end of March. The costs mainly related to the winding down of the Coast and Shore trials, for wet age-related macular degeneration. Each of them enrolled close to 1000 patients, so they were meaty studies. Following the March 24 trial bombshell, in April the company shed its workforce by 65%. In June four directors – half the board – departed. Future uncertain Under the terms of a development funding agreement (DFA), Opthea could owe investors somewhere between nothing and US$680 million. Given Opthea has US$170 million of debt, any bumper return would be hypothetical. Opthea 'remains in active negotiations with its DFA investors to deliver an outcome that is in the best interests of the company and its shareholders'. Opthea shares have not traded since the March disaster, so any passer-by from Mars would think they are still valued at 60 cents for a $738 million market cap. The only bright note is the company earned US$700,000 of interest. Microx shares surge on US deal Microx shares this morning went on a 33% share romp after the device maker announced a US customer for its Rover mobile X-ray units. The customer has requested anonymity, but it's a "top tier US healthcare group" that runs 700 hospitals. The company says the three year deal is subject to normal commercial conditions, but it does not quantify the expected revenue. Given the share surge, investors presume it's kinda, like, material. Polynovo shakes off The Troubles Wound repair house PolyNovo (ASX:PNV) has shrugged off corporate governance issues by reporting a strong recovery in revenue and profits. At its full-year results later next month, Polynovo should report sales of $118.6 million for the year to June 2025, up 30% year on year. Second (June) half cash flow swung to a positive $15.7 million, compared with a $12.5 million deficit in the first half. Management expects full-year earnings before interest tax depreciation and amortisation of $11.2-12.4 million. This compares with the previous year's $3.6 million. Of the revenue, $88.4 million derived from the US, up 29%. The company gleaned most of its sales from its flagship product, Novosorb BTM. 'I like to review the year and the go-forward from a high level and all I see is growth and opportunity,' chairman David Williams chirps. In mid-March the company said CEO Swami Raote would depart, amid claims of bullying and inappropriate behaviour against Williams. The board engaged independent lawyers to probe the claims. It also bought in former Westpac chairman Lindsay Maxsted to advise the board on governance matters. The unashamedly outspoken Williams denies any wrongdoing and like the Irish, The Troubles seem to be forgotten. Macquarie Equities similarly is enthused, ascribing a $2.45 per share valuation relative to yesterday's closing value of $1.22. 'We see several near-term positive catalysts for Polynovo, with a significant longer-term opportunity in additional indications.' Yesterday, peer Kiwi wound repair house Aroa Biosurgery (ASX:ARX) also found investor favour after reporting its third successive quarter of positive cash flow, of NZ$1.7 million. Aroa has guided to revenue of NZ$92-100 million for the year to March 2026, with normalised underlying earnings of NZ$5-8 million. Emvision's Emu trial is in full stride… Portable brain (stroke) detection device maker EMvision Medical Devices (ASX:EMV) says its pivotal trial to support FDA approval is 'progressing well'. Pertaining to the company's lightweight bedside unit Emu, the trial is recruiting up to 300 stroke patients across four US and two Australian high-volume stroke centres. A variant for road and air ambulances, First Responder has been trialled by the Royal Flying Doctor Service. A Melbourne stroke ambulance has also had a look-see. Emvision recorded June quarter outflows of $2 million, taking cash to $10.5 million. But the company will benefit from a non-dilutive $5 million grant from the Industry Growth Program, to develop First Responder. The aforementioned Microx is also developing a portable head CT scanner to diagnose strokes. … while Actinogen's trial recruitment passes halfway mark Actinogen Medical (ASX:ACW) reports that its keenly anticipated phase 2b/3 Alzheimer's disease study has enrolled 123 of the targeted 220 patients. Dubbed Xanamia, the trial has recruited across 20 US and 15 Australian sites, targeting patients with mild to moderate progressive Alzheimer's. Actinogen's compound Xanamem targets elevated levels of a protein called pTau181. The novel mechanism of action inhibits production of cortisol, which is toxic to the brain in excessive amounts. Having recruited its 100 th patient, Xanamia is subject to an interim 'futility' review next January. This will determine whether the trial is worth continuing. With Xanamia hotting up, Actinogen disclosed June quarter cash outflows of $5.1 million, leaving June-end cash of $16.5 million. The company also has access to a $3 million loan, the first component of a $13.8 million advance of expected research and development tax incentives. Often a supplement to equity raisings, R&D loans have become increasingly popular with biotechs seeking to bring forward cash flow. Ozempic maker's fat profits become thinner The fate of Europe's biggest drug maker shows that boom conditions in the drug-making game rarely last – even with miracle fat-busting drugs. The maker of the anti-obesity and diabetes drugs Ozempic and Wegovy, Denmark's Novo Nordisk overnight issued a profit warning that sent the shares tumbling up to 28% on the Nasdaq Copenhagen exchange. The company slashed its outlook for 2025 sales growth to between 8-14%, from between 13-21% previously. According to Reuters, sales have been affected by custom-made compounded drugs that emulate the branded versions. The US bars pharmacies from replicating approved drugs, but allows 'compounding' for patients needing custom doses or formulations. Dial 'L' for loophole. The company also faces turmoil from the abrupt removal in May of CEO Lars Fruergaard Jorgensen. The board replaced him with veteran insider Maziar Mike Doustdar. Slowing fat drug sales aside, Doustdar also faces the prospect of a 15% tariff on goods imported into the US. 'We need to increase the sense of urgency and execute differently,' Doustdar told investors. Sounds about right.
